CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...

We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

In a groundbreaking study, scientists from China have successfully created mice with two biological fathers. Though the ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Barclays cut their price target on shares of CRISPR Therapeutics from $59.00 to $55. ...

From the moment the first rate cut occurred, long-term interest rates ... “You know, I want to own, I want to own CRISPR because I keep seeing their name come up and all the science papers ...

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease. Casgevy, also ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.A novel ...

An Oxfordshire university student is among those set to receive a "transformative" gene-therapy treatment on the NHS for sickle ...